Avita Medical taps ex-Novartis exec Perry for CEO as it shifts focus to US | Personnel Moves June 9, 2017

Avita Medical (ASX:AVH) said last week it tapped former Novartis (NYSE:NVS) global biz dev & licensing chief scientific officer Dr. Michael Perry as its new chief executive officer, replacing resigning CEO Adam Kelliher. Dr. Perry served as a non-exec director of Avita since Feb 2013, according to the company, and held positions with Novartis including chief scientific officer of various units and VP of its integrated hospital care franchise and stem cell therapy global head. He has also served as bioscience R&D global head of Baxter (NYSE:BAX), regulatory affairs VP at Sandoz Pharma and Syntex Corp as well as chair, CEO and CMO at several early stage biotech companies. The company said it made a decision to retain a US-based CEO after the board determined the company’s achievement of US-based milestones would drive company value, and London-based Kelliher elected to not relocate and resigned from his position. Avita said Kelliher will stay on as a consultant to the board. “We are most grateful to Mr Kelliher for his significant contributions to Avita during his tenure. He oversaw a diversity of critical company achievements; most notably progress of our clinical programs, strategic capital raises and continued progress on our BARDA contract. We are also appreciative of the keen focus and energy he brings to his work, qualities we are sure he will apply in his future endeavours. Mike’s expertise across the value chain in cell therapy along with his ex...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Atlas Ventures Avalere Health Avita Baxter bectondickinson BioSig Technologies Integrated Healing Technologies Integrity Applications LimFlow Novartis Nuvasive PerkinElmer Inc. personnel-moves Polaris Pa Source Type: news